(Q33891529)

29 July 2017

0 references

Network meta-analysis of survival data with fractional polynomials (English)

1 reference

29 July 2017

1 reference

1

Jeroen P Jansen

1 reference

29 July 2017

6 May 2011

1 reference

BMC Medical Research Methodology

29 July 2017

1 reference

29 July 2017

11

1 reference

29 July 2017

61

1 reference

Creative Commons Attribution 2.0 Generic

29 July 2017

start time

6 May 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

exact match

https://scigraph.springernature.com/pub.10.1186/1471-2288-11-61

0 references

cites work

Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112194

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112194

Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112194

A new proposal for multivariable modelling of time-varying effects in survival data based on fractional polynomial time-transformation

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112194

Bayesian methods for evidence synthesis in cost-effectiveness analysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112194

Simultaneous comparison of multiple treatments: combining direct and indirect evidence.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112194

Combination of direct and indirect evidence in mixed treatment comparisons

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112194

Flexible meta-regression functions for modeling aggregate dose-response data, with an application to alcohol and mortality

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112194

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112194

Keeping data continuous when analyzing the prognostic impact of a tumor marker: an example with cathepsin D in breast cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112194

Borrowing strength from external trials in a meta-analysis.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3112194

Additive and multiplicative covariate regression models for relative survival incorporating fractional polynomials for time-dependent effects.

5 July 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-11-61

Dynamic Cox modelling based on fractional polynomials: time-variations in gastric cancer prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-11-61

Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: Application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-11-61

Bayesian measures of model complexity and fit

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-11-61

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-11-61

Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1186%2F1471-2288-11-61

Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

21 January 2018

1 reference

12 December 2020

Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study

1 reference

12 December 2020

Platinum-based second-line treatment in non-small-cell lung cancer: an old new kid on the block?

1 reference

12 December 2020

Network meta-analysis for indirect treatment comparisons

1 reference

12 December 2020

Identifiers

DOI

10.1186/1471-2288-11-61

1 reference

PubMed ID

21548941

Dimensions Publication ID

29 July 2017

1 reference

https://scigraph.springernature.com/pub.10.1186/1471-2288-11-61

9 September 2019

1 reference

29 July 2017

1 reference

PubMed ID

21548941